Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN loss |
Therapy | Bevacizumab + Everolimus |
Indication/Tumor Type | meningioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | meningioma | predicted - sensitive | Bevacizumab + Everolimus | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Afinitor (everolimus) and Avastin (bevacizumab) resulted in a partial response with a progression-free survival of 382 days in a meningioma patient with PTEN loss (by IHC) (PMID: 39143272). | 39143272 |
PubMed Id | Reference Title | Details |
---|---|---|
(39143272) | Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors. | Full reference... |